spacer
home > ebr > summer 2017 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

“It is important that rare disease businesses bring treatments to market as early as possible to give patients the best chance,” say Sobi’s Hege Hellström and Neil Dugdale in our summer 2017 industry Q&A. This captures the essence of therapy research and development for these often life-limiting illnesses affecting an estimated 70,000 patient groups. Access to the therapy, not just producing and commercialising it, should be a priority.

‘Salami-slicing’ of mass market, non-rare diseases to create artificial orphan indications is increasingly blurring lines between big pharma and specialised focus, according to The Weinberg Group’s Matthew Weinberg and Emily Krulewitz. Its driver is seemingly pharmacogenomics and the ability to stratify patients inside a group based on their genome and consequent response to particular therapies, switching them to personalised medicines.

Hermann Mascher at pharm-analyt Labor reminds us of the transformational potential these patient-specific therapeutics offer, and that particular biochemical pathways’ missing or defective components can be both the biomarker to identify a disease’s subset and the therapy to restore that deletion. If these could be characterised by bioanalytical methodologies serving a range of conditions, more synthetic forms of these endogenous small molecules may come on stream in development as therapeutics.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Amcor partners with Moda to offer innovative packaging solutions

Amcor is pleased to announce its partnership with Moda vacuum packaging systems in North America and Latin America. By combining Amcor’s shrink bag and rollstock film for meat and cheese with Moda’s system, producers can gain operational efficiencies and drive total cost savings.
More info >>

White Papers

The Emerging Use of Social Media in Orphan Disease Drug Research

Worldwide Clinical Trials Ltd

The use of various social media platforms, such as Twitter, Instagram, Facebook, and LinkedIn, for dissemination of clinical trial information has created a cornucopia of possibilities enabling clinical trial performance. Characterized by a people-to-people immediacy, social media permits extraordinarily adaptive modification of study information in real-time, and it does so in a highly targeted fashion.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement